Two medicines, side by side
Olodaterol vs tiotropium
Olodaterol and tiotropium are both labeled for COPD. Drugs@FDA records approvals of olodaterol since 2014 and of tiotropium since 2004. Pharmacies paid $65.94 per gram (Striverdi respimat inhal spray) and $11.81 per tiotropium 18 mcg capsule-inhaler (NADAC, October 7, 2026); the strengths differ and one is a brand and one a generic, so the two prices are not like for like. In FDA's classes, olodaterol is a beta2-adrenergic agonist and tiotropium an anticholinergic.
Check it at the source: the olodaterol FDA label on DailyMed (effective January 3, 2025); the tiotropium FDA label on DailyMed (effective November 10, 2025).
Highlights of the olodaterol record
Olodaterol (Striverdi) · label of January 3, 2025
Used for
From the label: indicationsSTRIVERDI RESPIMAT Inhalation Spray is a long-acting beta 2 -adrenergic agonist (LABA) indicated for: The long-term, once-daily maintenance bronchodilator treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema. ( 1.1 ) Important limitations: STRIVERDI RESPIMAT is NOT indicated to treat acute deterioration of COPD. […]
On the market
- Earliest approval on file
- July 31, 2014
- Generic labelers
- none listed
- Pharmacy cost
- $65.94 per gram
Supply and safety
- Shortage
- No current entry
- Recalls
- 0
Highlights of the tiotropium record
Tiotropium (Spiriva) · label of November 10, 2025
Used for
From the label: indicationsSPIRIVA HANDIHALER (tiotropium bromide inhalation powder) is indicated for the long-term, once-daily, maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema. SPIRIVA HANDIHALER is indicated to reduce exacerbations in COPD patients. […]
On the market
- Earliest approval on file
- January 30, 2004
- Generic labelers
- 1 labeler
- Pharmacy cost
- $11.81 per capsule
Supply and safety
- Shortage
- No current entry
- Recalls
- 5
Source: FDA drug labels via openFDA (Olodaterol label of January 3, 2025, Tiotropium label of November 10, 2025); NDC Directory, Drugs@FDA, NADAC, FDA shortages and recalls (October 8, 2026)
How do olodaterol and tiotropium differ on the record?
In FDA's classes, olodaterol is a beta2-adrenergic agonist and tiotropium an anticholinergic.
How each works, in its label's words: Olodaterol, “Olodaterol is a long-acting beta 2 -adrenergic agonist (LABA).”; Tiotropium, “It has similar affinity to the subtypes of muscarinic receptors, M 1 to M 5 .”
Half-life, in each label's words: Olodaterol, “The terminal half-life following intravenous administration is 22 hours.”; Tiotropium, “Elimination The terminal half-life of tiotropium in COPD patients following once daily inhalation of 5 mcg tiotropium …”
Generics: olodaterol none approved; tiotropium since 2023 (Drugs@FDA).
| Olodaterol | Tiotropium | |
|---|---|---|
| Labeled for | COPD | COPD, Asthma |
| Pharmacologic class | beta2-Adrenergic Agonist | Anticholinergic |
| How it works (label) | Olodaterol is a long-acting beta 2 -adrenergic agonist (LABA). The compound exerts its pharmacological effects by binding and activation of beta 2 -adrenoceptors after topical administration by inhalation. | Tiotropium is a long-acting, antimuscarinic agent, which is often referred to as an anticholinergic. It has similar affinity to the subtypes of muscarinic receptors, M 1 to M 5 . |
| Half-life (label) | The terminal half-life following intravenous administration is 22 hours. | Elimination The terminal half-life of tiotropium in COPD patients following once daily inhalation of 5 mcg tiotropium was approximately 25 hours. |
| Earliest approval on file (Drugs@FDA) | July 31, 2014 | January 30, 2004 |
| First generic approved | none | June 20, 2023 |
| Generic labelers (NDC) | none listed | 1 labeler |
| Pharmacy cost (NADAC, each one's most listed form; strengths differ) | $65.94 per gram (Striverdi respimat inhal spray) | $11.81 per capsule (Tiotropium 18 mcg capsule-inhaler) |
| 12-month price change | +3% | -5% |
| Boxed warning | No | No |
| Shortage now | No current entry | No current entry |
| Recalls recorded | 0 | 5 |
| FAERS reports (a report is not proof of cause; counts follow how widely a medicine is used) | 370 | 146,625 |
| DEA schedule | none | none |
Source: Drugs@FDA, FDA NDC Directory, CMS NADAC of October 7, 2026, FDA shortages and recalls, FAERS via openFDA (FDA files October 8, 2026)
What do the labels say about using others of their kind?
Tiotropium label, drug interactionsAvoid administration of SPIRIVA HANDIHALER with other anticholinergic-containing drugs.
Source: FDA drug labels via openFDA
What next?
- Alternatives to olodaterol
- every medicine labeled for the same conditions